CD274 and urinary bladder cancer: To assess baseline developmental trajectories in bladder cancer, and how these are affected by immunotherapy, we performed pseudotime analysis on blood and tumors from the 2 standard-of-care patients with bladder cancer who did not receive any preoperative systemic therapy (Untreated A and B), together with the 3 trial patients treated with atezolizumab (Anti-PD-L1 B–D, who had blood both pre- and posttreatment, and posttreatment tumor; Supplemental Dataset 1), and examined results from these groups separately.